CSPC Pharmaceutical Group (HK:1093) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group Limited has made a notable advancement in the pharmaceutical market with their latest product, Amphotericin B Liposome for Injection, receiving drug registration approval in China. This product, designed to treat systemic fungal infections, febrile neutropenia in suspected fungal infections, and visceral leishmaniasis, also reduces nephrotoxicity and improves therapeutic outcomes due to its innovative liposomal delivery system.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.